Creso Pharma (CPH) is considering speeding up its planned U.S....

• Creso Pharma (CPH) is considering speeding up its planned U.S. entry after a psychedelics bill passed through the Californian Senate
• Senate Bill 519 essentially paves the way for the use and possession of psilocybin and other psychedelic compounds to be legalised
• CPH has labelled the news encouraging, as it continues to progress the planned acquisition of Halucenex — a Canadian psilocybin business
• Creso has appointed a Director of U.S. Business Development and a Strategic Advisor as it works to progress the Halucenex partnership
• The company will also accelerate its agreement with U.S. scientific consulting firm, HetereoGeneity, to facilitate a faster market entry

Read the Full Article on The Market Herald here